参考文献/References:
[1] 周达新,潘文志,吴永健,等. 经导管主动脉瓣置换术中国专家共识（2020更新版）[J]. 中国介入心脏病学杂志,2020,28(6):301-309.
[2] Leon MB,Mack MJ,Hahn RT,et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk[J]. J Am Coll Cardiol,2021,77(9):1149-1161.
[3] van Mieghem NM,Schipper ME,Ladich E,et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement[J]. Circulation,2013,127(22):2194-2201.
[4] Chakravarty T,S?ndergaard L,Friedman J,et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves:an observational study[J]. Lancet,2017,389(10087):2383-2392.
[5] Généreux P,Cohen DJ,Mack M,et al. Incidence,predictors,and prognostic impact of late bleeding complications after transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2014,64(24):2605-2615.
[6] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2021,77(4):e25-e197.
[7] Chakravarty T,Patel A,Kapadia S,et al. Anticoagulation after surgical or transcatheter bioprosthetic aortic valve replacement[J]. J Am Coll Cardiol,2019,74(9):1190-1200.
[8] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur J Cardiothorac Surg,2021,60(4):727-800.
[9] Carroll JD,Mack MJ,Vemulapalli S,et al. STS-ACC TVT registry of transcatheter aortic valve replacement[J]. Ann Thorac Surg,2021,111(2):701-722.
[10] Makkar RR,Blanke P,Leipsic J,et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves:PARTNER 3 cardiac computed tomography substudy[J]. J Am Coll Cardiol,2020,75(24):3003-3015.
[11] Mentias A,Desai MY,Saad M,et al. Incidence and outcomes of acute coronary syndrome after transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2020,13(8):938-950.
[12] Isogai T,Saad AM,Ahuja KR,et al. Incidence,treatment,and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement[J]. Catheter Cardiovasc Interv,2022;99(3):877-888.
[13] Panchal HB,Ladia V,Desai S,et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis[J]. Am J Cardiol,2013,112(6):850-860.
[14] Arai T,Romano M,Lefevre T,et al. Direct comparison of feasibility and safety of transfemoral versus transaortic versus transapical transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2016,9(22):2320-2325.
[15] Piccolo R,Pilgrim T,Franzone A,et al. Frequency,timing,and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2017,10(14):1436-1446.
[16] Rodes-Cabau J,Masson JB,Welsh RC,et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve:the ARTE(aspirin versus aspirin＋clopidogrel following transcatheter aortic valve implantation) randomized vlinical trial[J]. JACC Cardiovasc Interv,2017,10(13):1357-1365.
[17] Brouwer J,Nijenhuis VJ,Delewi R,et al.Aspirin with or without vlopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med,2020,383(15):1447-1457.
[18] Stabile E,Pucciarelli A,Cota L,et al. SAT-TAVI(single antiplatelet therapy for TAVI) study:a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation[J]. Int J Cardiol,2014,174(3):624-627.
[19] Dangas GD,Tijssen JGP,Wohrle J,et al. A controlled rrial of rivaroxaban after transcatheter aortic-valve replacement[J]. N Engl J Med,2020,382(2):120-129.
[20] Park H,Kang DY,Ahn JM,et al. Rationale and design of the ADAPT-TAVR trial:a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement[J]. BMJ Open,2021,11(1):e042587.
[21] Kuno T,Takagi H,Sugiyama T,et al. Antithrombotic strategies after transcatheter aortic valve implantation:insights from a network meta-analysis[J]. Catheter Cardiovasc Interv,2020,96(2):E177-E186.
[22] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg,2018,53(1):34-78.
[23] Ten Berg J,Sibbing D,Rocca B,et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation:a consensus document of the ESC working group on thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI),in collaboration with the ESC council on valvular heart disease[J]. Eur Heart J,2021,42(23):2265-2269.
[24] Abdul-Jawad Altisent O,Durand E,Mu?oz-García AJ,et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2016,9(16):1706-1717.
[25]Nijenhuis VJ,Bennaghmouch N,Hassell M,et al. Rationale and design of POPular-TAVI:antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation[J]. Am Heart J,2016,173:77-85.
[26] Collet JP,Berti S,Cequier A,et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis:the randomized ATLANTIS trial[J]. Am Heart J,2018,200:44-50.
[27] van Mieghem NM,Unverdorben M,Valgimigli M,et al. Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial[J]. Am Heart J,2018,205:63-69.
[28] van Mieghem NM,Unverdorben M,Hengstenberg C,et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR[J]. N Engl J Med,2021,385(23):2150-2160.
[29] Makkar RR,Fontana G,Jilaihawi H,et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves[J]. N Engl J Med,2015,373(21):2015-2024.
相似文献/References:
[1]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(6):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[2]王斯佳 王国兴.抗栓治疗后消化道出血的现状及抗栓策略[J].心血管病学进展,2020,(8):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
WANG Sijia,WANG G uoxing.Current Characteristics and Anti-thrombotic Strategy of Gastrointestinal Hemorrhage after Anti-thrombotic Therapy[J].Advances in Cardiovascular Diseases,2020,(6):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
[3]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[4]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(6):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(6):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(6):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
[7]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(6):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[8]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(6):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[9]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(6):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[10]金冉阳 刘德敏 崔炜.经皮冠状动脉介入治疗围手术期抗栓治疗的演变[J].心血管病学进展,2023,(1):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
JIN Ranyang,LIU Demin,CUI Wei.Evolution of Antithrombotic Therapy During Perioperative PCI[J].Advances in Cardiovascular Diseases,2023,(6):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
[11]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[12]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(6):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]